Zwingenberg, Germany
BRAIN Biotech AG is a German biotechnology company with a focus on developing sustainable industrial processes in the fields of nutrition, health, and the environment. Established in 1993, the company is a leading European supplier of biobased products and solutions such as enzymes, proteins, microbial production strains, and natural compounds.
The company's business activities are divided into three segments: BioProducts, BioScience, and BioIncubator. The BioProducts segment operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States, focusing on specialty enzymes and other proteins. The BioScience segment offers custom solutions based on enzyme technology, strain development, and natural product screening. The BioIncubator segment is involved in high value-added R&D projects, including the development of a CRISPR-based gene editing technology platform.
With a €5.00M Post-IPO Debt investment at 29 February 2024 from MP Beteiligungs, BRAIN Biotech AG continues to expand its efforts in industrial biotechnology and remains committed to delivering innovative biobased solutions for a more sustainable future.
Holiferm
